Fundamental Analysis of AGENUS INC(NASDAQ:AGEN) stock

Fundamental Rating

Taking everything into account, AGEN scores 2 out of 10 in our fundamental rating. AGEN was compared to 588 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AGEN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.

AGEN had a negative operating cash flow in the past year.

In the past 5 years AGEN always reported negative net income.

In the past 5 years AGEN reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -78.38%, AGEN is doing worse than 70.55% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-78.38%
ROE	N/A
ROIC	N/A

ROA(3y)-45.6%

ROA(5y)-58.14%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of AGEN (97.98%) is better than 98.46% of its industry peers.

AGEN's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	97.98%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.25%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

AGEN has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, AGEN has more shares outstanding

The debt/assets ratio for AGEN is higher compared to a year ago.

2.2 Solvency

AGEN has an Altman-Z score of -10.24. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of AGEN (-10.24) is worse than 75.86% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-10.24

ROIC/WACCN/A

WACC9.12%

2.3 Liquidity

A Current Ratio of 0.44 indicates that AGEN may have some problems paying its short term obligations.

AGEN's Current ratio of 0.44 is on the low side compared to the rest of the industry. AGEN is outperformed by 96.06% of its industry peers.

AGEN has a Quick Ratio of 0.44. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.44, AGEN is doing worse than 95.72% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.44
Quick Ratio	0.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for AGEN have decreased strongly by -1168.35% in the last year.

Looking at the last year, AGEN shows a very strong growth in Revenue. The Revenue has grown by 59.49%.

AGEN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.55% yearly.

EPS 1Y (TTM)-1168.35%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-983.33%

Revenue 1Y (TTM)59.49%

Revenue growth 3Y21.02%

Revenue growth 5Y33.55%

Revenue growth Q2Q195.07%

3.2 Future

The Earnings Per Share is expected to grow by 14.71% on average over the next years. This is quite good.

AGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.68% yearly.

EPS Next Y96.7%

EPS Next 2Y38.92%

EPS Next 3Y24.89%

EPS Next 5Y14.71%

Revenue Next Year61.03%

Revenue Next 2Y29.43%

Revenue Next 3Y35.85%

Revenue Next 5Y34.68%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AGEN's earnings are expected to grow with 24.89% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.92%

EPS Next 3Y24.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AGEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AGENUS INC

NASDAQ:AGEN (4/25/2024, 7:00:00 PM)

After market: 8.37 +0.07 (+0.84%)

8.3

+0.88 (+11.86%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap173.88M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-78.38%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	97.98%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.5

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.44
Quick Ratio	0.44
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-1168.35%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y96.7%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)59.49%

Revenue growth 3Y21.02%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

AGENUS INC (AGEN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens